A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years

NCT06106581 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

304

Enrollment

INDUSTRY

Sponsor class

Conditions

Chikungunya Virus Infection

Interventions

BIOLOGICAL: VLA1553 full dose
BIOLOGICAL: VLA1553 half dose
BIOLOGICAL: Control

Sponsor

Valneva Austria GmbH